Lv58
1210 积分 2025-03-26 加入
Strategies to reduce the use of non-human primates in the development of oncology therapeutics: CD3-bispecifics
46分钟前
待确认
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
4天前
已完结
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
12天前
已完结
Application of Empirical Scalars To Enable Early Prediction of Human Hepatic Clearance Using In Vitro-In Vivo Extrapolation in Drug Discovery: An Evaluation of 173 Drugs
27天前
已完结
Factor XIa–specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis
1个月前
已完结
CD28 co-stimulation: novel insights and applications in cancer immunotherapy
1个月前
已完结
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
3个月前
已完结
Abstract 5821: DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors
3个月前
已关闭
A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Subjects
4个月前
已关闭
皖公网安备34019202002308
